New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 12, 2012
23:40 EDTCELG, BEAM, P, CMG, KORS, STO, TSCO, AGN, SLE, AUQ, DRI, GLD, SHW, HD, COV, CHK, RNDY, WPRT, ESRX, TITNJim Cramer's "Mad Money"
Jim Cramer said, "2012 is no longer about global economic crisis, it's about buying stock in the companies you love." Cramer said he's no longer sweating the details of every story that hits the news wires. Because the big-money players, those who would sell on every bit of negative news, are simply no longer a part of this market. They have been replaced by good old-fashioned individual investors. When companies break up, investors win, Cramer reminded viewers, as he highlighted yet another corporate breakup story, Sara Lee (SLE). He said that shares of Sara Lee should follow in the footsteps of Beam (BEAM) and Covidien (COV), two other breakup stocks, which headed markedly higher. Sara Lee is offering a $3-a-share special dividend to shareholders when the breakup occurs. Additionally, recent analysis of Sara Lee's various components values the stock 22% higher than where it trades today. Sara Lee plans to update shareholders on its progress at an investors meeting on June 5. Investing in Sara Lee will be a slow climb, said Cramer, which is why he would use recent weakness in the stock to get in at attractive prices. Continuing with his week-long series of great American growth stocks, Cramer turned the spotlight onto Allergan (AGN). It is not only a health care company that treats eye problems and migraines, but it is also a leader in medical aesthetics, including Botox and great implants. Cramer said that Allergan has multiple years of growth ahead of it. Its end markets are huge. Also, Allergan is highly competitive in every arena in which it enters and the company pays a tiny dividend. Shares trade for just 19x earnings and the company has a 14% long-term growth rate. Giving investors another great American growth stock, Cramer also highlighted Celgene (CELG), another stock just off its 52-week high. Celgene has one of the fastest growth rates in its sector, said Cramer, and also huge market potential as a host of new products and new applications for existing products are chugging toward FDA approval. Internationally, the company is a powerhouse. Cramer said that while Celgene is unlikely to offer a dividend anytime soon, the company has done a few well-timed stock buybacks to reward shareholders. Celgene sports a rock-solid balance sheet. Celgene trades at just 13.8x next year's earnings, despite the company's 24% growth rate. NO HUDDLE OFFENSE: Cramer said that the tailwinds are all lining up for a great quarter at Home Depot (HD), and he would be a buyer of the stock, even up near its 52-week high. Case-in-point: Tractor Supply (TSCO) announced sales that are double what analysts are expecting and Titan Machinery (TITN) pre-announced strong earnings, followed by Sherwin-Williams (SHW) announcing sales up by 20%. LIGHTNING ROUND: (Bullish) STO; ESRX; GLD; KORS; WPRT; DRI; CMG; RNDY. (Bearish) AUQ; P; CHK. Reference Link
News For SLE;BEAM;COV;AGN;CELG;HD;TSCO;TITN;SHW;STO;ESRX;GLD;KORS;WPRT;DRI;CMG;RNDY;AUQ;P;CHK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 12, 2015
19:33 EDTCELGCelgene takes stake in Australia's Mesoblast, the Australian says
Subscribe for More Information
April 10, 2015
10:54 EDTCMGChipotle moves higher, levels to watch
Subscribe for More Information
10:25 EDTCMGChipotle rises over 4% to near $679 per share in early trading
Subscribe for More Information
06:19 EDTGLDSPDR Gold Trust overall implied volatility at 15; 26-week average is 17
April 9, 2015
14:15 EDTESRXExpress Scripts calls active on elevated volatility on sharp rally
Express Scripts April weekly 87 and April 90 calls are active on total call volume of 20K (2K puts). April weekly call option implied volatility is at 38, April is at 26, May is at 30, June is at 25; compared to its 26-week average of 22 according to Track Data, suggesting large near term price movement.
10:02 EDTSTOStatoil makes oil discovery in Gulf of Mexico
Statoil (STO) announced that it has made an oil discovery in its Miocene Yeti prospect located in the Gulf of Mexico. The Yeti discovery expands the proven sub-salt Miocene play further South and West of Big Foot," said Jez Averty, Statoil's senior vice president, exploration for North America. "We are analyzing data to determine the size of the discovery in order to consider future appraisal options." The Yeti discovery was made in Walker Ridge block 160, which is located approximately 15 km (9 miles) south of the Big Foot field, and 11 km from the Cascade field. All of the blocks making up Yeti were accessed by the current owners in recent years. Yeti was drilled with the Maersk Developer drilling rig, a sixth generation semi-submersible. Statoil reports that its drilling efficiency with Yeti was among the best of any well drilled in Walker Ridge, achieving a drilling performance level of approximately 120 meters per day. The rig has moved on and is currently drilling Statoil's Thorvald prospect in the Mississippi Canyon block 814. Statoil is the operator of Yeti, and its partners are Anadarko (APC) and Samson (SSN).
10:00 EDTAUQOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:18 EDTHDBofA/Merrill retail analysts hold an analyst/industry conference call
Subscribe for More Information
08:36 EDTAUQAuRico Gold upgraded to Buy from Hold at Canaccord
Subscribe for More Information
06:06 EDTGLDSPDR Gold Trust overall implied volatility at 15; 26-week average is 17
Subscribe for More Information
April 8, 2015
09:37 EDTAUQAuRico Gold upgraded to Buy from Hold at Desjardins
07:03 EDTGLDSPDR Gold Trust overall implied volatility at 15; 26-week average is 18
Subscribe for More Information
April 7, 2015
08:44 EDTPPandora has 3 to 1 reward to risk ratio, says SunTrust
Subscribe for More Information
07:24 EDTCELGCelgene Otezla has growing opportunity, says Bernstein
After interviewing small groups of New York City area dermatologists, Bernstein believes that Celgene's psoriasis,treatment, Otezla, has a growing opportunity, due to its oral dosing, convenience, and lack of immunosuppression. The firm quotes doctors as saying that the drug serves as a useful "stepping stone," for patients who might need more intensive therapy, but want to postpone or avoid biologic Bernstein keeps a $158 price target and Outperform rating on Celgene.
06:47 EDTGLDSPDR Gold Trust overall implied volatility at 16; 26-week average is 18
05:57 EDTCMGStocks with implied volatility above IV index mean; CMG DDD
Subscribe for More Information
April 6, 2015
10:02 EDTPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:33 EDTGLDSPDR Gold Trust rallies on weaker Jobs Report, dollar
The ETF is up 1.7% to $117.23 At that price next resistance is at $117.79. The move up in early trading puts price back above the 50-day moving average at $116.29, which is bullish price behavior.
07:57 EDTESRXLeerink healthcare services analyst holds analyst/industry conference call
Healthcare Services Analyst Gupte discusses the leverage Anthem likely has in its Pharmacy Benefit Manager (PBM) contract with Express Scripts and how it changes after the Catamaran-Optum Rx deal, the synergy potential for the deal between Catamaran and Optum Rx and the likelihood of Cigna-HS remaining with the newly merged Optum Rx-CTRX on an Analyst/Industry conference call to be held on April 6 at 2 pm.
06:27 EDTPPandora initiated with a Hold at Axiom
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use